Hassan Yousefnia
Nuclear Science and Technology Research Institute (NSTRI)
[ 1 ] - Evaluation of the Possible Utilization of 68Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer
Objective(s): Studies have indicated advantageous properties of [DOTA-DPhe1 , Tyr3 ] octreotide (DOTATOC) in tumor models and labeling with gallium. Breast cancer is the second leading cause of cancer mortality in women, and most of these cancers are often an adenocarcinoma. Due to the importance of target to non-target ratios in the efficacy of diagnosis, the pharmacokinetic of 68Ga-DOTATOC in...
[ 2 ] - Preclinical Studies of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs
Objective(s): Gallium-68 DOTA-DPhe1-Tyr3-Octreotide (68Ga-DOTATOC) has been applied by several European centers for the treatment of a variety of human malignancies. Nevertheless, definitive dosimetric data are yet unavailable. According to the Society of Nuclear Medicine and Molecular Imaging, researchers are investigating the safety and efficacy of this radiotracer to meet Food and Drug Admin...
[ 3 ] - Preliminary Dosimetry Study of 67Ga-AATS for Human Based on Biodistribution Data in Rats
Introduction Gallium-67 (67Ga) has been used as a radionuclide for imaging a variety of solid tumors since 1969. Since then use of various gallium-based radiotracers has been reported. Recently, 67Ga-labeled acetylacetate bis(thiosemicarbazones) (67Ga-AATS) complex with significant tumor accumulation and fast blood clearance has been employed. Materials and Methods In this study, the absorbed d...
[ 4 ] - Preparation, quality control and biodistribution study of 68Ga-BPAMD: Optimized production with an in-house 68Ge-68Ga generator
Introduction: Bone metastases are common in the progression of various tumors leading to severe pain and decrease in quality of life. The aim of this study was to optimize the production of 68Ga-BPAMD as an ideal bone imaging agent using an in-house 68Ge/68Ga generator for future clinical use. Methods: The optimized condit...
[ 5 ] - Pharmacokinetic studies and human absorbed dose estimation of 68Ga-(4 {[(bis (phosphonomethyl)) carbamoyl] methyl}-7,10-bis(carboxymethy l) -1,4,7,10-tetraazacyclododec-1-yl) acetic acid
Background: In this study, human absorbed dose of a newly introduced bone imaging agent, 68Ga-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (68Ga-BPAMD), was estimated based on the rats data. Materials and Methods: 68Ga was obtained from the 68Ge/68Ga generator and it's radionuclidic and radiochemical purities were investigate...
Co-Authors